SCHEMBL4453028

SCHEMBL4453028

c1ccc(OCc2nc(-c3ccc(Nc4ccncc4)cc3)c[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.40
PRMT5 O14744 1/20 0.39
ACP1 P24666 1/20 0.39
RAB9A P51151 4/20 0.39
LMNA P02545 1/20 0.39
KCNH2 Q12809 1/20 0.38
GRIN2B Q13224 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 2/20 0.37
NPC1 O15118 2/20 0.37
TP53 P04637 1/20 0.37
ROCK2 O75116 1/20 0.37
GRK2 P25098 1/20 0.37
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
GSK3B P49841 2/20 0.36
CAMK2D Q13557 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4453029 0.92 RAB9A (0.40) RAB9AKCNH2SMN1; SMN2TSHRNPC1
SCHEMBL4470351 0.88 IKBKB (0.42) ACP1RAB9ASMN1; SMN2TSHRNPC1
SCHEMBL4464942 0.85 SCN5A (0.36) PRMT5RAB9ASMN1; SMN2TSHRNPC1
SCHEMBL4456749 0.85 PRMT5 (0.43) PRMT5RAB9ASMN1; SMN2TSHRNPC1
SCHEMBL4465047 0.84 PRMT5 (0.42) PRMT5RAB9AKCNH2SMN1; SMN2TSHR
SCHEMBL4460180 0.84 ENPP3 (0.35) RAB9ALMNASMN1; SMN2TSHRNPC1
SCHEMBL4456536 0.84 SYK (0.37) RAB9ASMN1; SMN2TSHRNPC1TP53
SCHEMBL4466562 0.83 RAB9A (0.45) RAB9AKCNH2SMN1; SMN2TSHRNPC1
SCHEMBL4461716 0.82 SYK (0.40) RAB9ASMN1; SMN2TSHRNPC1TP53
SCHEMBL4456488 0.81 ENPP3 (0.35) RAB9ALMNASMN1; SMN2TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 F2 4255/4885PRMT5 442/4885ACP1 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.